Blueprint Medicines Corporation

Other

Harvard College

Dana-farber-cancer Institute Inc.

Chandrasekhar V Miduturu

Neil Bifulco

Joseph L Kim

Brian Lewis Hodous

Lucian V DiPietro

Steven Mark Wenglowsky

Natasja Brooijmans

Yulian Zhang

Douglas Wilson

Jason D Brubaker

Emanuele Perola

Thomas A Dineen

Joshua T Close

Michael J Burke

Nathanael Schiander Gray

Priscilla Yang

Margaret J Clark

Lucian V Dipietro

Brian L Hodous

Jr Bifulco Neil

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

MAP4K1 inhibitors

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

Compounds and compositions useful for treating disorders related to NTRK

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I): 

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Inhibitors of the fibroblast growth factor receptor

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I: 

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

Disclosed herein are pyrimidine compounds of formula I and formula II and methods for treating or preventing a viral infection, such as infections caused by dengue virus in a subject, comprising administering to said subject an effective amount of a pyrimidine compound of formula I or formula II.

Substituted heterocyclic compounds for treating or preventing viral infections

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

Compounds and compositions useful for treating disorders related to Kit are described herein.

Compositions useful for treating disorders related to kit

Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.

Growing community of inventors

Cambridge, MA, United States of America

Chandrasekhar V Miduturu